Los Angeles Times

Hims & Hers abandons plan for cheaper Wegovy knockoff after FDA warning

This is read by an automated voice. Please report any issues or inconsistencies here. Telehealth company Hims & Hers dropped its plan to offer a knockoff version of ...
Business Insider

MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism

CARMEL, Ind., March 09, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel ...
Inc

RFK Jr.’s Plan for Easier Access to Peptides Clashes With FDA Safety Concerns

Robert F. Kennedy Jr. said over the weekend that he plans to loosen regulations around selected peptides. While the drugs have been exploding in the media, many of them haven’t been approved in the ...
Inc

A New FDA Plan Could Transform Treatment Access for Rare Disease Patients

Federal health officials yesterday issued a proposal that would make it easier for patients with rare diseases to receive treatment. If approved, the Food and Drug Administration’s new policy would ...
Penn Live

Gene editing treatments could get easier FDA approval under new plan

WASHINGTON (AP) — Federal health officials on Monday laid out a proposal to spur development of customized treatments for patients with hard-to-treat diseases, including for rare genetic conditions ...
The Hill

Cassidy unveils FDA modernization plan

Sen. Bill Cassidy (R-La.), chair of the Senate Committee on Health, Education, Labor and Pensions, unveiled his proposal to modernize the Food and Drug Administration (FDA), calling for innovation and ...
Seeking Alpha

Market AM Need to Know: Trump's coal power plan, Moderna FDA setback, and more

Stock index futures were higher on Wednesday as traders looked forward to January’s nonfarm payroll report. Now, here are five news stories that broke overnight to watch out for: Trump unveils coal ...
Becker's Hospital Review

FDA debuts domestic pharma supply chain plan

The FDA will begin accepting applications Feb. 1 for its PreCheck pilot program, an initiative designed to strengthen the domestic pharmaceutical supply chain. The program aims to increase regulatory ...
Business Wire

INTENT Biologics Receives FDA Agreement Granting a Full Waiver for its Pediatric Study Plan for PEP Biologic™ in Advanced Wound Care

ROCHESTER, Minn.--(BUSINESS WIRE)--INTENT Biologics, a clinical-stage biotechnology company developing PEP Biologic as the first-in-class exosome-based biologic therapies for serious conditions with ...